Biophan's Biothermal Power Source for Implantable Medical Devices Awarded ''Best of the Best'' by Nanotech Briefs Magazine; Nanotech Briefs' ''Nano 50 Awards'' to Honor the Company's Biothermal Battery at Official Awards Ceremony.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation medical technology, announced today that its biothermal power source for implantable devices has been recognized as a "Best of the Best" invention by Nanotech Briefs magazine as part of its first annual Nano 50 Awards contest to recognize superior scientific achievement and innovation. Developed by Biophan subsidiary TE-Bio, the biothermal power source converts body heat into electricity to power implantable medical devices.

"This latest validation of our biothermal power source further distinguishes Biophan's groundbreaking work in the field of nanotechnology and thermoelectric materials by a panel of expert judges," said Biophan CEO Michael Weiner. "It's always gratifying when our advanced solutions receive outside recognition for their innovation, functionality, and potential for impact on biomedical and other market sectors. We are proud of this recognition and we look forward to formally accepting the Nano 50 "Best of the Best" honor at the Nanotech Briefs awards ceremony."

The nominations for the Nano 50 were judged by a panel of nanotechnology and MEMS experts. The technologies, products, and innovators receiving the 50 highest scores were named winners of the Nano 50 "Best of the Best" awards. Presented by Nanotech Briefs magazine, a digital publication from the publishers of NASA Tech Briefs, the Nano 50 recognizes the top 50 technologies, products, and innovators that have significantly impacted, or are expected to impact, the state of the art in nanotechnology.

Based on innovations in thermoelectric materials, Biophan's biothermal power source converts thermal energy produced naturally by the human body into usable electrical energy. These thermoelectric materials are special types of semiconductors that produce electricity when there is a temperature difference between one side of the material and the other. These materials have been used to generate electricity on spacecraft, such as the Voyager space probe. The power they generate can be used to directly power implanted devices such as pacemakers, neurostimulators, biosensors, drug pumps, lab-on-a-chip devices, pain devices, and other implantable devices, or to trickle-charge batteries for devices with high discharge requirements, such as implantable cardiac defibrillators (ICDs) and drug pumps.

Biophan's nanotechnology applications span a range of existing and emerging multi-billion-dollar markets in biosciences and healthcare. The biothermal power source was developed by Biophan research and development subsidiary TE-Bio. Biophan's TE-Bio subsidiary has an agreement with NASA for characterization and joint development of high-density, nanoengineered thermoelectric materials for use with implantable medical devices. Research is being jointly conducted by Biophan and NASA personnel at the NASA Ames Research Center for Nanotechnology in Moffett Field, CA.

The Nano 50 will be presented at a special awards dinner during the NASA Tech Briefs Nano 2005 conference in Boston, November 11-12, 2005.

About Nanotech Briefs

Nanotech Briefs, launched in January 2004, is a digital (PDF format) magazine from the publishers of NASA Tech Briefs - the country's largest-circulation design engineering magazine - that provides the best of government, industry and university nanotech innovations with real-world applications in areas such as electronics, materials, sensors, manufacturing, biomedical, optics/photonics, and aerospace/defense. Nanotech Briefs is the first small-tech publication specifically for design engineers who are designing tomorrow's nanotech products today. For more information, please visit www.nanotechbriefs.com.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 140 U.S. patents, licenses, or applications. This total includes 38 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 93 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.